Research and Development (R&D) activities within inflammatory disorders have been discontinued by Novo Nordisk ,however increasing its efforts in diabetes prevention and treatment.
Surprisingly this announcement follows company's decision to discontinue anti-IL-20 , which used in rheumatoid Arthritis which was company's most advanced compound.
As a result of this discontinuation company expects to incur a non recurring cost of around 700 million Danish Krona in 2014.Company Executive Vice President said that significant unmet opportunities remain within diabetes, including prevention ,obesity and diabetes complications , so in this area they want to further increase R&D efforts.
Surprisingly this announcement follows company's decision to discontinue anti-IL-20 , which used in rheumatoid Arthritis which was company's most advanced compound.
As a result of this discontinuation company expects to incur a non recurring cost of around 700 million Danish Krona in 2014.Company Executive Vice President said that significant unmet opportunities remain within diabetes, including prevention ,obesity and diabetes complications , so in this area they want to further increase R&D efforts.